Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: the private financial adviser in last weeks

the private financial adviser in last weeks

posted on Feb 28, 2006 09:17AM
news story that stirred it up about PTSC ... well he did point out a weakness in PTSC and that is the dilution. But in so doing, he pointed out to Pohl as to what the next big thing he could do to increase shareholder value --- buy back shares. Reduce dilution. Of course it will take more contracts to do that and more contracts mean a higher share price which takes more money to buy back more shares which takes more contracts ... would there be more bang for the buck to buy back shares instead of a dividend next year ...
Share
New Message
Please login to post a reply